Clinical Trial

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-03.
Status change: Not Yet Recruiting → Recruiting 2024-10-10
Trial Details
NCT Number NCT05487391
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 632 participants
Start Date 2022-12-08
Primary Completion 2027-08-31 (estimated)
Study Completion 2029-05-22 (estimated)
Updated on ClinicalTrials.gov 2024-10-15